BRAF Kinase Inhibitors Market Introduction

BRAF is a human gene that encodes the BRAF protein. The BRAF protein is more formally known as serine/threonine-protein kinase BRAF. The BRAF gene is also known as VRAF murine sarcoma viral oncogene homolog B and proto-oncogene BRAF. BRAF is a member of the RAF kinase family of growth signal transduction protein kinases. These proteins play an important role in regulating the MAP kinase signaling pathway. The signaling pathway affects cell differentiation, division, and secretion. Mutation in BRAF proteins can cause certain types of cancer including colorectal cancer and melanoma. Blocking mutated BRAF kinase proteins can help in inhibition of growth of cancerous cells. Hence, certain types of BRAF kinase inhibitors are used to treat a few types of cancer. BRAF kinase inhibitors are used as targeted therapy drugs for the treatment of non-small-cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), and melanomas caused by mutations of the BRAF gene. These drugs directly target the BRAF protein and inhibit the growth of cancerous cells in patients with metastatic melanoma.

Identify the key factors that will drive your company’s growth. Request a brochure of this report here

BRAF Kinase Inhibitors Market – Competitive Landscape

The global BRAF Kinase inhibitors market is consolidated with very few global players accounting for major market share in international market. Leading biopharmaceutical companies have made significant investments in clinical research studies in to address the untapped market. In June 2017, the Food and Drug Administration (FDA) approved Dabrafenib and Trametinib regimen for the treatment of a rare subset of non?small-cell lung carcinoma (NSCLC)

Bayer AG

Incorporated in 1863, Bayer AG is based in Leverkusen, Germany. It is a chemical and pharmaceutical company that markets products, helping prevent, diagnose, and treat diseases for humans and animals. The pharmaceutical division emphasizes on prescription products and specialty therapeutics in the areas of cardiology, women’s health, hematology, oncology, and ophthalmology.

F. Hoffmann-La Roche AG

Founded in 1896, F. Hoffmann-La Roche AG is headquartered in Basel, Switzerland. It is a global biopharmaceutical company engaged in the development, manufacture, and commercialization of pharmaceutical products and medical devices. Roche Pharmaceuticals is a world leader in biotechnology and oncology.

Novartis AG

Novartis AG founded in 1996 in Switzerland is a global health care company that develops, manufactures, and provides high-quality drugs and health care services. The company operates through three business segments: innovative medicines, Sandoz, and Alcon. The company’s innovative medicines business division operates through two units: Novartis Pharmaceuticals and Novartis Oncology. The Novartis Oncology unit develops therapeutic treatments in the fields of oncology and rare diseases.

Array BioPharma Inc.

The Array BioPharma Inc. is the U.S. based biopharmaceutical company founded in the year 1998. The company is primarily focused of clinical research, development and commercialization of targeted small molecules drugs against the treatment of cancer and high burden disorders.

Expanding operations in future? To get the perfect launch ask for a custom report here

BRAF Kinase Inhibitors Market Dynamics

High prevalence of non-small-cell lung carcinoma (NSCLC) is likely to be key contributing factor for the growth of BRAF Kinase Inhibitors Market.

The BRAF kinase inhibitors market is primarily driven by increase in the rate of incidence and prevalence of cancers such as metastatic melanoma and non-small-cell lung carcinoma (NSCLC). Melanoma is reported as the most common type of cancer worldwide with estimated, age-standardized incidence rates of 2.8–3.1 per 100,000 people. According to the American Cancer Society, about 96,480 new patients with melanomas would be diagnosed in the U.S. by the end of 2019. Out of these, about 39,260 would be women and 57,220 would be men. About 7,230 people are expected to die of melanoma. According to a study published in ‘Cancer.Net’, lung cancer is the second-most common cancer and it is a leading cause of cancer deaths among both men and women. Around 142,670 deaths are likely to be caused by lung cancer by the end of 2019. Non-small-cell lung carcinoma (NSCLC) is the most common type of lung cancer; it accounts for 84% of all lung cancer diagnoses.

Large number of clinical trial pipeline drugs and anticipated commercialization by various companies is one of the key driving factors during the forecast period.

The global BRAF kinase inhibitors market is expected to expand at a rapid pace during the forecast period. Research and development activities by key market players have increased over the last few years. They are focusing on extending the research on BRAF kinase inhibitors for other applications. Furthermore, several BRAF kinase inhibitor drugs are at the final stage of research and development and are expected to be launched during the forecast period.

BRAF Kinase Inhibitors Market – Segmentation

  • Product Type
  • Distribution Channel
  • Region

BRAF Kinase Inhibitors Market – By Product Type

  • Sorafenib
  • Vemurafenib
  • Encorafenib
  • Dabrafenib

BRAF Kinase Inhibitors Market – By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

The report on BRAF Kinase Inhibitors market is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The BRAF Kinase Inhibitors market report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The BRAF Kinase Inhibitors market report also maps the qualitative impact of various market factors on BRAF Kinase Inhibitors market segments and geographies.

Regional analysis for BRAF Kinase Inhibitors market includes:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa (MEA)

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

.